Nexalin Regains Nasdaq Bid Price Compliance, Faces Jan 4 Equity Test

Nexalin Technology, Inc. (Nasdaq: NXL) said on October 8, 2026 that Nasdaq confirmed it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), after its closing bid price held above $1.00 per share for 21 consecutive trading days, from August 31 through September 29, 2026. The confirmation was dated September 30, 2026. A Nasdaq Hearings Panel decision dated September 25, 2026 granted the company's request for continued listing and now requires it to demonstrate compliance with the $2.5 million minimum stockholders' equity standard by January 4, 2027.

Context — Why the Nasdaq Compliance Clock Still Runs for NXL

The bid price hurdle is cleared. The equity hurdle is not, and the report gives no comparable prior-period figure for stockholders' equity, no balance sheet total, and no stated plan for how the shortfall will be closed. That absence is the story for anyone tracking the ticker.

What changed to trigger the event now was mechanical. The company completed a reverse stock split it had previously announced, and that split lifted the closing bid price above the $1.00 floor for the required 21-session window. The report does not disclose the split ratio, the pre-split share price, or the share count.

Nasdaq's confirmation, dated September 30, 2026, arrived five days after the Panel's September 25 decision granting continued listing. The Panel attached conditions rather than closing the matter: the equity test must be met on or before January 4, 2027, and the company must promptly notify the Panel of any significant events during the exception period that could affect compliance.

The Panel also reserved the right to reconsider the terms of the exception. That reservation keeps delisting risk live even though the bid price issue is resolved.

CEO Mark White framed the compliance news as secondary to operations, saying the company's "primary focus remains on the growing momentum across our business." He pointed to a distribution agreement covering Brazil and six additional South American markets, and to U.S. clinical programs including the pivotal HALO Clarity trial in insomnia.

The macro backdrop is not addressed in the report, so no rate, index, or sector benchmark can be attached to this specific filing.

Data — What the Bid Price and Equity Figures Show

The measurable facts sit in two columns: what Nasdaq required, and what the tape delivered.

Item	Detail
Bid price threshold	Above $1.00 per share
Consecutive sessions above threshold	21 trading days
Window	August 31 to September 29, 2026
Nasdaq confirmation date	September 30, 2026
Panel decision date	September 25, 2026
Equity requirement	$2.5 million minimum stockholders' equity
Equity deadline	January 4, 2027

Before the split, the bid price sat below the $1.00 minimum long enough to trigger the deficiency and the Panel process. After the split, it held above $1.00 for 21 straight sessions. The report gives neither the pre-split price nor the split ratio, so the size of that move cannot be quantified from the disclosure.

The company also did not disclose its current stockholders' equity balance, the size of any gap against the $2.5 million threshold, or the financing steps it may pursue. No market capitalization, share count, or revenue figure appears in the release.

For comparison, the report offers one adjacent datapoint rather than a peer set: the Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. That is a regulatory footprint, not a financial one, and it does not substitute for the equity number Nasdaq is waiting on.

Analysis — What It Means for NXL Holders and Small-Cap Listings

The second-order effect is concentrated in one place: the January 4, 2027 equity test. Regaining bid price compliance removes the immediate delisting trigger, but the Panel's exception is conditional, and the Panel can revisit its terms. A company that fails the equity standard by that date faces renewed listing pressure.

For holders, the practical exposure is dilution risk. Satisfying a $2.5 million stockholders' equity minimum typically requires either operating earnings, an equity raise, or a conversion of liabilities into equity, and the report names none of these as a chosen path. It lists "the Company's planned initiatives to strengthen its balance sheet" among its forward-looking statements without describing them.

The commercial side carries its own execution risk. The South American distribution agreement depends on the distributor meeting purchase and payment obligations, and on obtaining and maintaining regulatory approvals in markets other than Brazil, where the device is already approved. The report does not name the distributor, the contract value, or the minimum purchase commitments.

A counter-argument deserves airing: the compliance win is real and it was earned over 21 sessions, not granted on a technicality. Nasdaq confirmed the price held above $1.00 through September 29, and the Panel granted continued listing. For a microcap, that removes a near-term overhang.

Positioning is where the report is thinnest. It gives no short interest, no institutional ownership, no float, and no volume data, so flow direction cannot be established from this disclosure. What can be said is that the equity deadline creates a defined event window that any holder or prospective holder must price.

Outlook — What to Watch Before January 4, 2027

The first catalyst is a disclosure of how the company intends to reach $2.5 million in stockholders' equity. The report commits to no method, so the next balance sheet update or financing announcement is the event to track.

The second is the January 4, 2027 deadline itself. That date is fixed by the Panel's decision. Any notification the company sends the Panel about significant events during the exception period is also material, because the Panel has reserved the right to reconsider.

The third is clinical and commercial progress. The pivotal HALO Clarity trial in insomnia and the pursuit of FDA marketing authorization for the DIFS technology are named by the company as ongoing. The South American distribution agreement's execution, including distributor payments and regulatory approvals outside Brazil, is the nearer-term commercial test.

No support or resistance levels, moving averages, or price targets can be drawn from the report, and none are supplied here. The only hard level in the disclosure is the $1.00 bid price floor, which the stock has now held for 21 sessions.

Frequently Asked Questions

What does regaining Nasdaq bid price compliance mean for NXL shareholders?

It means the immediate delisting trigger tied to the $1.00 minimum bid price is resolved, based on 21 consecutive sessions above that level from August 31 to September 29, 2026. It does not resolve the separate requirement to show $2.5 million in minimum stockholders' equity by January 4, 2027. The Panel's exception remains conditional and can be reconsidered, so listing risk is reduced rather than eliminated.

Why did Nexalin need a Nasdaq Hearings Panel decision at all?

The company's closing bid price fell below the $1.00 minimum required under Listing Rule 5550(a)(2), which put it out of compliance. It requested continued listing, and the Panel granted that request on September 25, 2026, subject to conditions. The company then satisfied the bid price condition following its previously announced reverse stock split, and Nasdaq confirmed compliance in writing on September 30, 2026.

What happens if Nexalin misses the January 4, 2027 equity deadline?

The report states that continued listing remains subject to the terms of the Panel's decision, and that there can be no assurance the company will demonstrate compliance with the stockholders' equity requirement in time. It also notes the Panel has reserved the right to reconsider the exception's terms. The company has not disclosed its current equity balance or any specific plan to close the gap.

Bottom Line

Nexalin has cleared Nasdaq's $1.00 bid price test, but its listing now rests on proving $2.5 million in stockholders' equity by January 4, 2027.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.